Tag: colorectal cancer

Pressmeddelanden

Isofol Medical receives approval to conduct its second clinical phase I/II study of Modufolin® in patients with colon cancer.

2012-04-16 09:49 Isofol Medical AB Isofol Medical AB has received approval from the Swedish Medical Products Agency (Läkemedelsverket) to start a randomized phase I/II pharmacokinetic and pharmacodynamic study of its lead candidate Modufolin® in patients with colon cancer.

First patient enrolled in Isofol Medical’s initial trial with Modufolin® for treatment of neoadjuvant rectal cancer

2011-04-15 08:50 Isofol Medical AB Isofol Medical AB today announced that the company has enrolled its first patient in the explorative phase I/II trial, LARS2, for the treatment of rectal cancer. A total of 43 to 58 patients will receive Isofol’s novel folate-based drug Modufolin® in combination with the anti-cancer drug Alimta®.

Stort intresse för göteborgsk life science

2010-09-16 17:25 Isofol Medical AB Göteborgsbaserade Isofol var ett av företagen som presenterade sig under eftermiddagen. Med en vial i handen kliver Anders Rabbe, företagets VD, upp på scenen. I den lilla flaskan finns resultatet av drygt 30 års forskning: läkemedelskandidaten Modufolin®.

Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee

2010-09-09 10:24 Sanofi Sanofi-aventis and Regeneron Pharmaceuticals, Inc. announced today that the Phase 3 VELOUR clinical trial of aflibercept (VEGF Trap) in patients with metastatic colorectal cancer (mCRC) will continue to completion as planned, with no modifications due to efficacy or safety concerns.

PledPharma reports positive results from cancer study

2010-06-24 09:37 Accelerator Nordic AB No serious side effects of the chemotherapy were observed in the patients who received PP-095 (mangafodipir), while several serious side effects (grades 3 and 4 on the 4-point NCI-CTCAE scale) were observed in the patients who received placebo.